I have spent 35 years raising capital and more recently commercializing medical devices. I have taken companies from a blank sheet of paper to nine-figure outcomes. I have built distribution networks across four continents and negotiated agreements in markets where a handshake still matters as much as the contract. And I can tell you with certainty that the most underestimated phase of any fundraise is the preparation.

Not the pitch. Not the investor meetings. Not the term sheet. The preparation.

Our team at VerAvanti is preparing for a significant (Series B) institutional round. What follows is a candid account of what that preparation actually requires. The specifics come from MedTech, but the discipline applies to any company raising any round. Seed, Series A, Series B, growth equity. The rigor scales with the size of the check. The process does not change.

If you are an entrepreneur approaching a raise of any size, this is the playbook nobody gives you.

1. The Financial Model Is Not a Spreadsheet. It Is Your Credibility.

Most founders treat their financial model as a forecasting tool. Investors treat it as a character test. The precision of your model signals the precision of your thinking. And that precision is earned through disciplined repetition, not inspiration.

We ran multiple exhaustive audit passes on our financial models. Each pass had a specific objective and each one strengthened the model in ways the previous pass could not reach.

First pass: Structural integrity. We confirmed that every formula pulled from the correct source cell, that cross-sheet references pointed to the intended rows, and that valuation outputs were computing from the right assumptions. Complex models evolve over months and through many hands. Structural verification ensures the architecture is sound before you test anything else.

Second pass: Formula coverage. In any workbook that evolves through multiple iterations, static values inevitably replace formulas. Someone copies a cell, pastes as values during a presentation, and forgets to restore the link. Multiply that across dozens of sheets and you have a model that looks dynamic but contains pockets of frozen data. This pass rebuilt every broken link.

Third pass: Presentation and edge cases. Pre-revenue periods generate misleading metrics if not handled properly. Operating expense ratios in the thousands of percent. Working capital metrics that produce absurd day-counts. This pass added conditional logic to suppress these artifacts and ensured that every investor-facing sheet told a clean, coherent story.

Fourth pass: Cross-model reconciliation. We maintained separate regional models, each with its own regulatory timelines, pricing structures, and distributor economics. This final pass confirmed that every regional model flowed into a consolidated view with zero discrepancies, and that every downstream document matched the consolidated output exactly.

By the end, every assumption was traceable. Every regional model reconciled. Every number in every investor document pointed back to a single source of truth.

The lesson: If your financial model cannot survive a hostile audit by a junior analyst with unlimited time and zero goodwill, it will not survive due diligence. Run your audit passes until the model stops changing. Then run one more.

2. The Document Library: Comprehensive and Internally Consistent

A financial model is necessary but not sufficient. Investors evaluate you through a constellation of documents, and every number in every document must reconcile to the model. A single contradiction between your deck and your memo, or between your memo and your model, and your credibility collapses.

Over the preparation period we produced a comprehensive library of investor-ready documents:

• A roadshow deck with named comparable transactions, scenario analysis using public market multiples, and a capital structure waterfall. Audited multiple times for visual alignment, data consistency, and narrative flow.

• A CEO investment memo incorporating the key de-risking factors specific to our stage: regulatory pathway, KOL commitments, international commercial traction, manufacturing readiness, and bridge financing backstop.

• An investor target list profiling institutional investors across VC, PE, family office, and strategic categories, with comparable investments and tailored approach strategies for each.

• A one-page teaser for initial outreach. A detailed FAQ anticipating the hardest questions investors will ask. A data room index. An exit roadmap with comparable transactions and public company benchmarks.

• Regional financial models for every target geography, each with its own regulatory inputs, installed base projections, and distributor margin structures.

• Interactive dashboards for real-time visualization of the key metrics investors care about most: revenue build, path to profitability, capital efficiency, and return profile.

Every document was validated against the financial model after each update cycle. When the model changed, every downstream deliverable was updated in the same session. This discipline is not optional. It is table stakes for any institutional raise.

3. The Contract Stack: Building Commercial Infrastructure in Parallel

Investors want to see commercial traction. In pre-commercial medtech, that means signed distribution agreements, vendor partnerships, and a legal infrastructure that signals you are ready to operate at scale the moment you have clearance and capital.

In parallel with the financial modeling work, we negotiated and executed distribution agreements across multiple continents. Each agreement went through multiple versions with tracked changes, required CEO briefing materials to explain the commercial logic, and included service warranty exhibits tailored to the specific regulatory and commercial environment of each region.

We also developed a tiered agreement framework: a comprehensive master agreement for strategic distributors with established infrastructure, and a streamlined version for new market entrants with an automatic upgrade trigger when commercial milestones are reached. This lets you deploy the right level of legal complexity for each partner without over-engineering early relationships or under-protecting mature ones.

Simultaneously, we redlined vendor MSAs and NDAs with multiple technology partners across cybersecurity, AI/ML platform development, regulatory consulting, and device security testing. Every contract was reviewed for governing law, IP ownership, indemnification structure, payment milestones, insurance requirements, and post-termination provisions.

In several cases, careful review caught template provisions that would have created meaningful exposure if signed without scrutiny. Indemnification structures that ran in only one direction. IP ownership clauses with overreaching assignment language. Payment terms completely disconnected from milestone delivery. Non-compete provisions that survived termination for years.

None of these were malicious. All of them were standard template language that vendors use across industries. But in the context of a pre-commercial company preparing for institutional investment, every signed contract becomes part of the due diligence record.

An unfavorable clause signed carelessly signals a management team that does not read what it signs.

The lesson: Read every contract yourself. Every clause. Every defined term. The cost of a missed provision is always higher than the cost of the review. And the investor who discovers it during diligence will question what else you missed.

4. Clinical Content: Evidence Packaging, Not Marketing

Investors in medical devices want to see that you understand your customer's clinical workflow, the health economics of your product, and the evidence base that supports adoption. This is not a marketing exercise. It is a clinical evidence packaging exercise. The distinction matters.

We built a content library spanning multiple clinical indications. Each piece was anchored to peer-reviewed literature and positioned against the results of major clinical trials. We developed hospital economics models showing the financial impact of our technology on specific procedures. We produced reimbursement analyses mapping our device to existing CPT codes across our lead commercial specialties.

We also produced thought leadership content targeting both physician and investor audiences. Every piece was structured to lead with the clinical insight, not the product.

The technology earns its place in the narrative by solving the problem the reader already cares about.

This content serves a dual purpose that many entrepreneurs miss. It builds market awareness and credibility with the physicians who will ultimately adopt your technology.

Simultaneously, it demonstrates to investors that the management team has deep domain expertise, understands the clinical evidence landscape, and can articulate a credible commercial thesis. Investors in medtech are not just buying your device. They are buying your team's ability to navigate a complex, regulated market.

5. The Stress Test: Questions Your CEO Must Answer Without Notes

Before you walk into a single investor meeting, your CEO needs to answer the hardest questions without notes. Not from a memorized script. From genuine internalized understanding of the business.

We built a formal objection handler covering every angle a skeptical analyst or experienced LP would probe: regulatory delay scenarios, competitive positioning, reimbursement risk, manufacturing scale-up challenges, key-person dependency, international execution risk, capital efficiency relative to milestones, exit pathway credibility, and cap table structure.

We then stress-tested the entire fundraise thesis using structured analytical frameworks to identify gaps in the narrative, missing proof points, and areas where the data room needed strengthening. This exercise produced a prioritized action list with clear owners and deadlines.

The goal is not to eliminate risk. Every sophisticated investor knows that risk cannot be eliminated in pre-commercial medtech. The goal is to demonstrate that you have mapped every risk, assessed its probability and impact, and built a credible mitigation plan for each one. That is what separates a fundable company from an unfundable one.

6. What I Would Tell My Younger Self

After 35 years of raising capital and building companies, here is what I know to be true:

Start with the model, not the deck. The pitch deck is the last document you should build, not the first. Every slide should be a visual expression of a number or insight that lives in the financial model. If you build the deck first, you will spend months retrofitting numbers to match slides instead of slides to match reality.

Audit with discipline, not anxiety. Financial model audits are not about finding mistakes. They are about building institutional-grade confidence through systematic rigor. Each pass should have a defined objective: structural integrity, formula coverage, presentation quality, cross-model reconciliation. Treat it as a quality management system, not a fire drill.

One source of truth. Always. Every number in every document must trace back to one cell in one workbook. The moment you have two versions of a revenue figure circulating in your document library, you have a credibility problem. Investors will find the discrepancy. They always do.

Read every contract yourself. Do not delegate contract review to people who do not understand the commercial implications. Governing law defaults, one-sided indemnification, overreaching IP clauses, and post-termination restrictions are not legal technicalities. They are business risks that belong on your risk register and in your board materials.

Preparation is the product. The quality of your preparation is the single strongest signal investors have about the quality of your execution. A team that produces a bulletproof data room, a reconciled financial model, and a coherent document library is a team that will execute post-funding. That signal is what investors are really evaluating when they look at your materials.

None of this is glamorous work. There is no single breakthrough moment. It is disciplined, repetitive effort: cell-by-cell verification, clause-by-clause review, draft-by-draft refinement.

But it is the work that separates funded companies from unfunded ones. And it is the work that separates companies that execute post-funding from companies that do not.

If you are preparing for a raise, start here. Build the foundation. Make it unbreakable. The investors will come.